Telcon RF Pharmaceutical (XKRX:200230) Debt-to-Equity : 0.67 (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Telcon RF Pharmaceutical Debt-to-Equity?

Telcon RF Pharmaceutical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩55,101 Mil. Telcon RF Pharmaceutical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩590 Mil. Telcon RF Pharmaceutical's Total Stockholders Equity for the quarter that ended in Dec. 2024 was ₩82,830 Mil. Telcon RF Pharmaceutical's debt to equity for the quarter that ended in Dec. 2024 was 0.67.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Telcon RF Pharmaceutical's Debt-to-Equity or its related term are showing as below:

XKRX:200230' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.11 Med: 0.36 Max: 0.97
Current: 0.67

During the past 12 years, the highest Debt-to-Equity Ratio of Telcon RF Pharmaceutical was 0.97. The lowest was 0.11. And the median was 0.36.

XKRX:200230's Debt-to-Equity is ranked worse than
75.55% of 818 companies
in the Drug Manufacturers industry
Industry Median: 0.27 vs XKRX:200230: 0.67

Telcon RF Pharmaceutical Debt-to-Equity Historical Data

The historical data trend for Telcon RF Pharmaceutical's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telcon RF Pharmaceutical Debt-to-Equity Chart

Telcon RF Pharmaceutical Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Equity

Get a 7-Day Free Trial

0.97

0.53

0.36

0.26

0.67

Telcon RF Pharmaceutical Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Equity	Get a 7-Day Free Trial															0.26	0.28	0.43	0.45	0.67

Competitive Comparison of Telcon RF Pharmaceutical's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Telcon RF Pharmaceutical's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Telcon RF Pharmaceutical's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Telcon RF Pharmaceutical's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Telcon RF Pharmaceutical's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Telcon RF Pharmaceutical Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Telcon RF Pharmaceutical's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(55100.901	+	589.712)	/	82829.551
	=	0.67

Telcon RF Pharmaceutical's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(55100.901	+	589.712)	/	82829.551
	=	0.67

Telcon RF Pharmaceutical (XKRX:200230) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Telcon RF Pharmaceutical Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Telcon RF Pharmaceutical's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Telcon RF Pharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Telcon RF Pharmaceutical Inc (XKRX:200230) » Definitions » Debt-to-Equity

Traded in Other Exchanges

N/A

Address

684, Dongtangiheung-ro, Giheung-gu, Gyeonggi-do, Yongin-si, KOR, 17102

Website

http://www.telcon.co.kr

Telcon RF Pharmaceutical Inc manufactures wireless communication equipment. It develops connectors for input and output ports, board-to-board, cable assembly, and board-to-mount used in wireless communication equipment. The company also supplies RF coaxial connectors. The company operates in the RF Division and Pharmaceuticals & Biotechnology segments. The majority of its revenue is generated from Pharmaceuticals & Biotechnology, which produces and sells liquids, tablets, pills, capsules, etc.

Telcon RF Pharmaceutical Headlines

No Headlines